Two decades of PARP inhibitor synthetic lethality in cancer

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• PARP inhibitors demonstrate selective killing of tumor cells with BRCA1 or BRCA2 deficiencies.
• This discovery led to the first targeted cancer therapy based on germline biomarkers.
• The work is recognized as a top 20 cancer discovery of the 21st century.

Purpose of the Study:

• To review the learnings from two decades of research on PARP inhibitors and synthetic lethality in cancer therapy.
• To highlight the impact of BRCA-related discoveries on clinical practice and future research directions.
• To underscore the significance of germline mutation testing as a companion diagnostic.

Main Methods:

• Review of fundamental biological discoveries and their translation into clinical applications.
• Analysis of the impact of PARP inhibitors on breast, ovarian, prostate, and pancreatic cancers.
• Exploration of the synthetic lethality concept and its broader implications for cancer treatment.

Main Results:

• PARP inhibitors provide effective, well-tolerated targeted therapies for specific cancer types.
• Germline BRCA1/BRCA2 mutation testing evolved from risk assessment to a companion diagnostic.
• The BRCA-PARP inhibitor interaction spurred research into other synthetic lethal targets.

Conclusions:

• Targeted therapies based on fundamental biology, like PARP inhibitors for BRCA-mutated cancers, have transformed patient care.
• The synthetic lethality principle offers a powerful framework for discovering novel cancer treatments.
• Continued exploration of functional redundancy in tumor cells promises further therapeutic advancements.